Federal Register / Vol. 83, No. 118 / Tuesday, June 19, 2018 / Notices 28431 

TABLE 1—LIST OF INFORMATION COLLECTIONS APPROVED BY OMB 

Title of collection OMB 

control No. 

Date 

approval 

expires 

Infant Formula Requirements .................................................................................................................................. 0910–0256 5/31/2021 

Premarket Notification for a New Dietary Ingredient ............................................................................................... 0910–0330 5/31/2021 

Regulations for In Vivo Radiopharmaceuticals Used for Diagnosis and Monitoring .............................................. 0910–0409 5/31/2021 

Guidance for Industry: Formal Dispute Resolution; Scientific and Technical Issues Related to Pharmaceutical 

Current Good Manufacturing Practice ................................................................................................................. 0910–0563 5/31/2021 

Requests for Inspection by an Accredited Person Under the Inspection for Accredited Persons Program .......... 0910–0569 5/31/2021 

Substances Prohibited from Use in Animal Food or Feed ..................................................................................... 0910–0627 5/31/2021 

Class II Special Controls Guidance Document: Labeling for Natural Rubber Latex Condoms Classified Under 

21 CFR 884.5300 ................................................................................................................................................. 0910–0633 5/31/2021 

Guidance for Industry: Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements 

During an Influenza Pandemic ............................................................................................................................. 0910–0701 5/31/2021 

Guidance on Consultation Procedures: Foods Derived From New Plant Varieties ............................................... 0910–0704 5/31/2021 

Human Subject Protection; Acceptance of Data From Clinical Investigations for Medical Devices ...................... 0910–0741 5/31/2021 

Food Labeling; Calorie Labeling of Articles of Food in Vending Machines and Nutrition Labeling of Standard 

Menu Items in Restaurants and Similar Retail Food Establishments ................................................................. 0910–0782 5/31/2021 

Guidance for Industry, Researchers, Patient Groups, and Food and Drug Administration Staff on Meetings with 

the Office of Orphan Products Development ....................................................................................................... 0910–0787 5/31/2021 

Food Allergen Labeling and Reporting .................................................................................................................... 0910–0792 5/31/2021 

Transfer of a Premarket Notification Clearance ...................................................................................................... 0910–0852 5/31/2021 

Dated: June 13, 2018. 

Leslie Kux, 

Associate Commissioner for Policy. 

[FR Doc. 2018–13098 Filed 6–18–18; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Ryan White HIV/AIDS Program Parts A 

and B Integrated HIV Planning 

Implementation Cooperative 

Agreement to John Snow, Inc. (JSI), 

U69HA30144 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice of non-competitive FY 

2018 supplemental award. 

SUMMARY: This noncompetitive 

supplement award to JSI will support 

and strengthen current Ryan White HIV/ 

AIDS Program (RWHAP) Part A and Part 

B priority setting and resource 

allocation processes to ensure people 

living with HIV are linked to care, 

remain engaged in care, and achieve 

viral suppression. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Rene Sterling, Acting Director, Division 

of State HIV/AIDS Programs, HIV/AIDS 

Bureau, HRSA; 5600 Fishers Lane, 

Room 09W50, Rockville, MD 20857; 

Phone: (301) 443–9017, Email: 

rsterling@hrsa.gov. 

SUPPLEMENTARY INFORMATION: 

Intended Recipient of the Award: JSI 

(U69HA30144). 

Amount of Non-Competitive Award: 

$300,000 in FY 2018. 

Period of Funding: July 1, 2018, 

through June 30, 2019. 

CFDA Number: No. 93.145. 

Authority: Sections 2606 and 2654(b) 

of the Public Health Service Act, as 

amended by the Ryan White HIV/AIDS 

Treatment Extension Act of 2009 (Pub. 

L. 111–87). 

Justification: In 2016, JSI was awarded 

a 3-year cooperative agreement under 

HRSA–16–082 RWHAP Integrated HIV 

Planning Implementation (CFDA 

93.145), authorized by Sections 2606 

and 2654(b) of the Public Health Service 

Act, as amended by the Ryan White 

HIV/AIDS Treatment Extension Act of 

2009 (Pub. L. 111–87). The cooperative 

agreement was established to provide 

technical assistance to RWHAP Parts A 

and B recipients and their planning 

bodies regarding: (1) The integration of 

HIV planning across prevention, care, 

and treatment service delivery systems; 

and (2) the development, 

implementation, monitoring, and 

evaluation of Integrated HIV Prevention 

and Care Plans. RWHAP Parts A and B 

recipients and planning bodies use 

Integrated Plans to better inform and 

coordinate HIV prevention and care 

program planning, resource allocation, 

and continuous quality improvement 

efforts to meet the HIV service delivery 

needs within their jurisdictions. 

The proposed supplemental funding 

will provide RWHAP Parts A and B 

recipients with additional technical 

assistance (TA) specifically focused on 

resource allocation planning and 

implementation. These additional TA 

activities will build upon data elements 

identified in the Integrated Plan and 

provide jurisdictions with strategies, 

tools, and resources to effectively 

allocate annual available resources to 

prioritize HIV unmet needs. The TA 

activities will be directed at addressing 

more efficient and proactive methods in 

the Priority Setting and Resource 

Allocation (PSRA) process to increase 

the ability of health care providers and 

systems to ensure people living with 

HIV are linked to care, remain engaged 

in care, and achieve HIV viral 

suppression. 

Dated: June 12, 2018. 

George Sigounas, 

Administrator. 

[FR Doc. 2018–13121 Filed 6–18–18; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 


daltland on DSKBBV9HB2PROD with NOTICES